BAB V. KESIMPULAN DAN SARAN
5.1.2. Khusus
1. Tampilan imunositokimia HER2/neu paling banyak dijumpai pada karsinoma duktus invasif.
2. Tampilan imunositokimia HER2/neu dipengaruhi oleh ada tidaknya reseptor HER2/neu pada penderita.
3. Tidak dijumpai perbedaan hasil tampilan HER2/neu pada sediaan kering dan basah.
5.2. Saran
Berhubung tampilan HER2/neu pada sediaan biopsi aspirasi menunjukkan hasil yang cukup baik maka direkomendasikan :
1. Melakukan pemeriksaan imunositokimia HER2/neu pada sediaan biopsi aspirasi terhadap penderita yang didiagnosa sebagai kanker payudara tanpa harus melakukannya pada jaringan histopatologi.
2. Melakukan pemeriksaan yang sama pada saat rekurensi dan metastasis lokal.
Perlu dilakukan penelitian lanjutan untuk mengetahui apakah terdapat perbedaan tampilan HER2/neu pada tumor primer dan tumor metastasis.
DAFTAR PUSTAKA
1. Nora DT, Giuliano AE. Breast cancer.In Berek JS, editor. Novak’s gynecology. 13th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. 1375 - 93.
2. Kanker payudara. Available from : http:// www.fortunestar.co.id.
3. Cotton RE. Breast in lecture notes on pathology, 4thed. New York: Blackwell Scientific Publications; 1992. p.53-5.
4. Lubis MND. Biopsi kerokan (scraping) sebagai alternatif potong beku (frozen section), perbandingan dan aplikasinya. Disampaikan pada Pidato pengukuhan jabatan guru besar dalam Ilmu Patologi Anatomi FK USU Medan. Medan: USU Press; 1999. h. 2 – 13.
5. Schnitt SJ, Millis RR, Hanby AM, Oberman HA. The breast. In Mills Stacey et al editors. Stenberg’s Diagnostic Surgical Pathology. volume IB, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004, p.332 - 3.
6. Kanker Payudara : Bagaimana Hindari Berbagai Ancaman. Available from : http://www.depkes.go.id.
7. Tambunan GW. Diagnosis dan tata laksana sepuluh jenis kanker terbanyak di Indonesia. Jakarta: EGC; 1991. h.25-51.
8. Lukito JS. Kanker payudara ditinjau dari segi patologi anatomi (tesis, unpublished data). Medan: Program Pendidikan Dokter Spesialis I Patologi Anatomi FK USU, 1993.
9. Kamarlis RK, Lukito JS. Gambaran hasil pemeriksaan biopsi aspirasi jarum halus dan histopatologi terhadap temuan lesi payudara di laboratorium
patologi anatomi Fakultas Kedokteran USU Medan periode Januari – Desember 2006 (studi retrospektif, unpublished data). Medan: Program Pendidikan Dokter Spesialis I Patologi Anatomi FK USU, 2007.
10. Rosai J, editor. Breast. Ackerman’s Surgical Pathology, vol. II. 9th ed. New York: Mosby; 2004. p.52 - 3, 2098-9.
11. Kissane JM, editor. Female reproductive system, Vol 6. New York: Churchill Livingstone; 1991. p. 208, 212, 215 - 218.
12. Chandrasoma P, Taylor CR. The breast. Concise Pathology, 3th ed. Los Angeles: McGraw-Hill International Edition; 2001. p. 815-29.
13. Bartow SA. Rubin E, Farbel JL editors. The breast. Pathology , 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1993. p.1039 - 46.
14. Breast cancer genes and inheritance. Available from :
http://familycancer.org/FamHist.5tm
15. Are hormone receptors are present? Available from :
http://www.breastcancer.org/illustration/100017html
16. Tapia C, Savic S, Wagner. Her2 gene status in primary breast cancer and matched distant metastasis. Breast Cancer Research. 2007: 9.
17. Her2 disease. Available from : http://www.genentech.medicine.htm
18. Tambunan GW. Penuntun biopsi aspirasi jarum halus. Jakarta: Hipokrates; 1990. h.1 - 21.
19. Histology and Immunocytochemistry. Avaiable from :
http://www.histologyandimmunocytochemistry.html#cytochem.
21. Kissane JM. The breast in Anderson’s Pathology, vol II, 9th ed. St Louis: Mosby; 1990. p.1726 - 48.
22. Sjamsuhidajat R. de Jong. Payudara dalam Buku ajar ilmu bedah. Jakarta: EGC; 2000. h.534 - 5.
23. Ellis EO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA. Eusebi V. The breast. In Tavasolli, Devilee, editor. Pathology and genetic of tumours of the breast and female genital organs / WHO classification of tumours. , Washington: IARC Press; 2003. p.10, 34 - 6.
24. Breast cancer genes and inheritance. Available from :
http://familycancer.org/FamHist.5tm
25. Scheuner MT. Hereditary breast cancer, in management of breast disease. Cedar – Sinai Medical Center. 2007.
26. Nadji M. Fernandez CG. Parvin. Immunohistochemistry of estrogen and progesterone receptors reconsidered. AmJClinPathol. 2005; 129:21 – 27. 27. Tan PH. Pathology of ductal carcinoma in situ of the breast : A
heterogeneous of greater understanding. Ann Acad Med Singapore. 2001; 30:671 - 6.
28. Stenkvist B. Bengtsson E, Nordin B. 1993, Histopathological systems of breast cancer classification : Reproducibility and clinical significance, J Clin Pathol. 2003; 36:392 - 8.
29. Fitzgibbons PL, L. James, Connolly. Breast : Protocol applies to all invasive carcinomas of the breast, Protocol revision date : January 2005 Based on AJCC/UICC, 6th ed.
30. Crum CP. The breast In Diagnostic gynecologic and obstetric pathology. Philadelphia: Elsevier; 2006. p. 802 – 3.
31. Lester SC. The breast. In Kumar, Abbas, Fausto, editor. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Elsevier; 2005. p. 96, 296, 1119 – 51.
32. Crum CP, Lester SC, Coran RS. The breast. In Kumar, Cotran, Robbins, editor. Robbins Basic Pathology. 7th ed. Philadelphia: Elsevier; 2003. p. 705 - 17.
33. Rosen PP. Breast Pathology. Vol I, 2nd ed. Philadelphia: Lippincott; 2001. p 236 - 56.
34. Lindholm K. Breast. In Orel SR, Steretti GF, Whitaker D, editors. Fine Needle Aspiration Cytology, 4th ed. Philadelphia: Elsevier; 2005. p. 166 – 8, 197 – 215.
35. Rosai J, editor. Breast. Ackerman’s Surgical Pathology, vol. II. 9th ed. New York: Mosby; 2004. p. 1791-3.
36. Koss, Leopold G. The Breast. Koss’ diagnostic cytology and its histopathologic bases. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 1551 - 4.
37. Tanigawa N. Breast cancer fine needle aspiration cytology specimens contain overexpressed genes. Oncology Report. 2006: 15(4) : 803 - 8.
38. Moriki T. Takashi T. Hormone reseptor status and HER2/neu overexpression determined by automated imunostainer on routinely fixed cytologic specimens from breast carcinoma : Correlation with histologic sections
determinations and diagnostic pitfalls (abstract). Diagnostic Cytopathology. 2006; 30(4) : 251 -6.
39. Nerurkar, Ashutosh and Osin P. 2003, The diagnosis and management of pre-invasive breast diasease the role of new diagnostic techniques, Breast Cancer Res . 2003; 5: 305 - 8.
40. Sloane, John P. Biopsy pathology of the breast. Biopsy pathology series 24, 2nd ed. New York: Arnold; 2001. p. 62 - 9.
41. Erb B. Available from : http://www.wikipedia.
42. Ross, Jeffrey S., Jonathan AF. The HER2/neu gene and protein in breast cancer: prognostic factor, predictive factor, and target for therapy. The Oncologist. 1998: 3; 237 - 252.
43. Ross, Jeffrey S, Jonathan AF. et al. The HER2/neu gene and protein in breast cancer 2003: Biomarker and targer of therapy. The Oncologist . 2003: 8 ; 307 - 25.
44. Reese, David M, Dennis JS. HER2/neu signal transduction in human breast and ovarian cancer. Stem Cell. 1998: 15 :1-8.
45. Birner, Peter, George O et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER2 protein expression in breast cancer. Clin Can Res. 2001: 7 : 1660 - 75.
46. Research Advocacy Network and NCCN. HER2 Testing: Summary for breast cancer patients. Based on the NCCN task force report: HER2 testing in breast cancer. 2006.
47. Osborne, Cynthia, Wiscall P, Tripathy D. Oncogenes and Tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. The Oncologist. 2004; 9 : 361 - 77.
48. Watters, Amanda. HER2/neu testing: What, How and Why ? (editorial) The Biomedical Scientist. 2003 September
49. Gabrijela K. Fine needle aspiration cytology. New York: Springer; 2006. p. 19 - 202, 226 - 7.
50. King, Bonnie L, Love SM, et al. The Fourth International Symposium on the Intraductal Approach to Breast Cancer. Santa Barbara, California; 10 – 13 March. Breast Cancer Research; 2005: 7 ; 198 - 204.
51. Pettinato, Guido, Manivel CJ. Invasive micropapillary carcinoma of the breast. Am J Clin Pathol. 2004; 121 : 6 : 854 - 66.
52. Cibas, Edmund S, Barbara, Ducatman. Cytology, 2nd ed. New York; Saunders: 2004. p. 231 - 40.
53. Sumiyoshi, Kazuhiru, Shibayama Y, et al. Detection of human epidermal growth factor receptor 2 protein and gene in fine nededle aspiration cytology specimens and tissue sections from invasive breast cancer: can cytology specimens take the place of tissue section? Oncology Reports. 2006; 15 ; 803 - 6.
54. Sumiyoshi, Tanigawa. Breast cancer fine needle apiration cytology specimens contain overexpressed genes, Oncology Reports. 2006; 15 ; 803 - 6.
55. Dabbs D. Diagnostic immunohistochemistry, 2nd ed. New York: Elsevier; 2006. p. 2, 559, 732 - 4.
56. Bancroft, John D, Gamble M. Theory and practice of histological techniques, 5th ed. New York: Churchil Livingstone; 2005. p. 422 - 3.
57. Miller, Keith. The Breast HER2 module in immunocytochemistry. 2007; 5 (4) ; 171 - 3.
58. Budiarto E. Metodologi penelitian kedokteran. cetakan pertama. Jakarta; EGC; 2004. h. 58 – 69.
59. Notoatmojo S. Metodologi penelitian kesehatan, edisi revisi. Jakarta: Rineka Cipta; 2004. h. 138 – 44.
60. Bilous M, Dowsett M, Hanna W, Isola J, et al. Current perspective on HER2 testing: A review of national testing guidelines.Mod Pathol 2003;16(2):173– 182.
61. Schnitt SJ, Jacobs TW. Current status of HER2 testing. Am J Clin Pathol 2001; 116:806-8.
62. Cardoso F, Leo AD, Larsimont D, Gancberg D, Rouas G, Dolci S, Ferreira F, Paesmans M, Piccart M. Evaluation of HER2,/?55, bcl-2, topoisomerase II-a, heat shock proteins 27and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Annals of Oncology 2001; 12: 615-20.
63. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy (abstract). International journal of cancer 2008; 122: 999-1004.
64. Broom RJ, Tang P, Simmons C, Bordeleau L, Malley FP, Miller N, Andrulis IL, Brenner DN, Clemons M. Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with time: Discordance rates between primary and metastatic breast pathology samples (supplement). Journal of Clinical Oncology 2007; 1024.
Lampiran 1
Data klinis, sitologi dan imunositokimia HER2/neu dari 47 sediaan sitologi payudara
No No. slide Umur Diagnosa Tampilan
imunositokimia HER2/neu
1 080034 56 Karsinoma duktus invasif 0
2 081244 83 Karsinoma duktus invasif +2
3 081254 35 Karsinoma duktus invasif 0
4 081262 50 Karsinoma lobular 0
5 081362 38 Karsinoma lobular DD/ KDI 0
6 081440 50 Karsinoma duktus invasif DD/Ca. lob 0
7 081451 25 Karsinoma duktus invasif 0
8 081469 25 Karsinoma duktus invasif +2
9 081492 25 Karsinoma duktus invasif 0
10 081517 56 Karsinoma lobular 0
11 081532 52 Karsinoma duktus invasif +1
12 081573 64 Karsinoma lobular 0
13 081647 35 Karsinoma duktus invasif 0
14 081685 28 Sistosarkoma filoides maligna 0
15 081697 56 Karsinoma duktus invasif 0
16 081710 67 Karsinoma lobular 0
17 081718 57 Karsinoma duktus invasif 0
18 081723 58 Karsinoma duktus invasif 0
19 081804 52 Sistosarkoma filoides maligna 0
20 081872 45 Karsinoma lobular +1
21 081872 45 Karsinoma lobular 0
22 082388 47 Karsinoma duktus invasif 0
24 082395 30 Karsinoma duktus invasif 0
25 082395 30 Karsinoma duktus invasif 0
26 082444 49 Karsinoma duktus invasif 0
27 082454 55 Penyakit Paget +1
28 082473 35 Sistosarkoma filoides maligna 0
29 082551 56 Karsinoma duktus invasif +3
30 082551 56 Karsinoma duktus invasif 0
31 082551 60 Karsinoma duktus invasif 0
32 082560 68 Karsinoma musinus +1
33 082756 68 Karsinoma musinus 0
34 082736 34 Karsinoma lobular 0
35 082817 38 Karsinoma duktus invasif 0
36 082849 37 Karsinoma lobular 0
37 082859 52 Karsinoma duktus invasif 0
38 083470 56 Penyakit Paget 0
39 087151 56 Karsinoma lobular 0
40 090043 47 Karsinoma duktus invasif +3
41 090055 40 Karsinoma duktus invasif 0
42 090081 44 Karsinoma lobular +1
43 090149 34 Karsinoma duktus invasif 0
44 SA/156/08 44 Karsinoma duktus invasif 0
44 SA/197/08 55 Karsinoma duktus invasif 0
45 SA/204/08 43 Karsinoma duktus invasif 0
46 Ny. E 40 Karsinoma duktus invasif 0
Keterangan tabel :
Cetak tebal : menunjukkan sediaan positif imunositokimia Tanda * : menunjukkan teknik sediaan apus kering
Prosentaseintensitas tampilan hasil pulasan imunositokimia HER2/neu pada sediaan sitologi :
- Skor 0 = negatif
- Skor +1 = ≤ 10% sel yang terpulas fokal atau hanya setempat dari membran sitoplasma
- Skor +2 = tampilan lemah atau moderate komplit pada membran sitoplasma pada ≥ 10% sel-sel tumor
- Skor +3 = tampilan kuat dan komplit pada membran sitoplasma ≥ 10% sel –sel tumor
Lampiran 2
Gambar 1. Karsinoma duktal invasif Gambar 2. Karsinoma duktal invasif (HER2/neu – 80x) (HER2/neu – 40x)
Skor 0 (negatif) Skor +1 (< 10% sel yang terwarnai +)
Gambar 3. Karsinoma duktal invasif Gambar 4. Karsinoma duktal invasif (HER2/neu – 80x) (HER2/neu – 400x)